The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript

Pediatr Blood Cancer. 2020 May;67(5):e28185. doi: 10.1002/pbc.28185. Epub 2020 Jan 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Aminopyridines
  • Anaplastic Lymphoma Kinase / antagonists & inhibitors*
  • Anaplastic Lymphoma Kinase / metabolism
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / pathology
  • Bone Neoplasms / therapy*
  • Carbazoles / administration & dosage*
  • Chemoradiotherapy*
  • DNA-Binding Proteins / metabolism
  • Female
  • Humans
  • Lactams
  • Lactams, Macrocyclic / administration & dosage*
  • Oncogene Proteins, Fusion / metabolism
  • Piperidines / administration & dosage*
  • Pyrazoles
  • RNA-Binding Protein FUS / metabolism
  • Rhabdomyosarcoma* / diagnostic imaging
  • Rhabdomyosarcoma* / metabolism
  • Rhabdomyosarcoma* / pathology
  • Rhabdomyosarcoma* / therapy
  • Transcription Factors / metabolism

Substances

  • Aminopyridines
  • Carbazoles
  • DNA-Binding Proteins
  • FUS protein, human
  • Lactams
  • Lactams, Macrocyclic
  • Oncogene Proteins, Fusion
  • Piperidines
  • Pyrazoles
  • RNA-Binding Protein FUS
  • TFCP2 protein, human
  • Transcription Factors
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • alectinib
  • lorlatinib